Statement of Ownership (sc 13g)
January 04 2021 - 2:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. )*
Yumanity Therapeutics, Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
98872L 102
(CUSIP Number)
December 22, 2020
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate
box to designate the rule pursuant to which this Schedule is filed:
|
*
|
The remainder of
this cover page shall be filled out for a reporting person’s initial filing on
this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
|
The information
required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 98872L 102
|
Schedule 13G
|
(1)
|
Names
of reporting persons.
|
Merck
& Co., Inc.
|
(2)
|
Check
the appropriate box if a member of a group
(see
instructions)
|
¨ (a)
¨ (b)
|
(3)
|
SEC
use only.
|
|
(4)
|
Citizenship
or place of organization.
|
New
Jersey
|
Number
of shares beneficially owned by each reporting person with:
|
|
|
(5)
|
Sole voting
power.
|
0
|
|
(6)
|
Shared voting power.
|
526,999
|
|
(7)
|
Sole dispositive power.
|
0
|
|
(8)
|
Shared dispositive power.
|
526,999
|
(9)
|
Aggregate
amount beneficially owned by each reporting person.
|
526,999
|
(10)
|
Check
if the aggregate amount in Row (9) excludes certain shares (see instructions).
|
¨
|
(11)
|
Percent
of class represented by amount in Row (9).
|
5.2%
|
(12)
|
Type
of reporting person (see instructions).
|
CO,
HC
|
CUSIP No. 98872L 102
|
Schedule 13G
|
(1)
|
Names
of reporting persons.
|
Merck
Sharp & Dohme Corp.
|
(2)
|
Check
the appropriate box if a member of a group
(see
instructions)
|
¨ (a)
¨ (b)
|
(3)
|
SEC
use only.
|
|
(4)
|
Citizenship
or place of organization.
|
New
Jersey
|
Number
of shares beneficially owned by each reporting person with:
|
|
|
(5)
|
Sole voting
power.
|
0
|
|
(6)
|
Shared voting power.
|
526,999
|
|
(7)
|
Sole dispositive power.
|
0
|
|
(8)
|
Shared dispositive power.
|
526,999
|
(9)
|
Aggregate
amount beneficially owned by each reporting person.
|
526,999
|
(10)
|
Check
if the aggregate amount in Row (9) excludes certain shares (see instructions).
|
¨
|
(11)
|
Percent
of class represented by amount in Row (9).
|
5.2%
|
(12)
|
Type
of reporting person (see instructions).
|
CO
|
CUSIP No. 98872L 102
|
Schedule 13G
|
Item 1.
Yumanity Therapeutics, Inc.
|
(b)
|
Address of issuer’s
principal executive offices
|
80 Guest Street, Suite 500
Boston, MA 02135
Item 2.
|
(a)
|
Name of person
filing
|
This Schedule 13G is being filed
on behalf of the following:
|
i.
|
|
Merck &
Co., Inc. (“Merck”)
|
|
ii.
|
|
Merck Sharp
& Dohme Corp. (“MSD”), which is a wholly owned subsidiary of Merck
|
Merck and MSD are collectively
referred to in this Schedule 13G as the “Reporting Persons”.
|
(b)
|
Address or principal
business office or, if none, residence
|
|
i.
|
|
The address
of the principal business office for Merck is: 2000 Galloping Hill Road, Kenilworth,
NJ 07033.
|
|
ii.
|
|
The address
of the principal business office for MSD is: One Merck Drive, Whitehouse Station, NJ
08889.
|
|
i.
|
|
Merck is
a New Jersey corporation.
|
|
ii.
|
|
MSD is a
New Jersey corporation.
|
|
(d)
|
Title of class
of securities
|
Common stock, par value $0.001
per share (“Common Stock”)
98872L 102
Item 3.
|
Statement Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c)
|
Not applicable.
CUSIP No. 98872L 102
|
Schedule 13G
|
|
(a)-(c)
|
The information
relating to the beneficial ownership of Common Stock by each of the Reporting Persons
set forth in Rows 5 through 9 and Row 11 of the cover pages hereto is incorporated
herein by reference.
|
The ownership percentage of
each Reporting Person set forth in Row 11 of the cover pages hereto has been calculated based on 10,094,783 shares of Common
Stock outstanding as of December 22, 2020, as disclosed in the Issuer’s Form 8-K filed with the SEC on December 30,
2020.
Item 5.
|
Ownership of 5 Percent or Less of a Class.
|
If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities,
check the following ¨
Item 6.
|
Ownership of More than 5 Percent on Behalf of Another Person.
|
Not applicable.
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported
on By the Parent Holding Company or Control Person.
|
The reported securities are
owned directly by MSD, which is a wholly owned subsidiary of Merck. Merck is an indirect beneficial owner of the reported securities.
Item 8.
|
Identification and Classification of Members of the Group.
|
Not applicable.
Item 9.
|
Notice of Dissolution of Group.
|
Not applicable.
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination
under §240.14a-11.
SIGNATURES
After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Dated: January 4,
2021
|
Merck & Co., Inc.
|
|
|
|
By:
|
/s/ Kelly Grez
|
|
|
Name: Kelly Grez
|
|
Title: Deputy Corporate Secretary
|
|
|
|
|
|
Merck Sharp & Dohme Corp.
|
|
|
|
By:
|
/s/ Jon Filderman
|
|
|
Name: Jon Filderman
|
|
Title: Vice President
|
EXHIBIT INDEX
Exhibit
|
Description
|
99.1.
|
Joint Filing Agreement
|
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024